Open Access Full Text Article

Developing and validation of high performance liquid chromatography method for determination of carboplatin-loaded Metal-organic framework materials

Toan Quyen Pham^{1,2,3}, Han Do Hoang^{1,2,3}, Thanh Truc Nguyen^{1,2,3}, Huong Thi Thanh Pham⁴, Linh Ho Thuy Nguyen^{1,5}, Tan Le Hoang Doan^{1,5}, Minh-Tri Le^{3,*}



Use your smartphone to scan this QR code and download this article

¹Vietnam National University Ho Chi Minh City, Ho Chi Minh city, Viet Nam

²University of Health Sciences, Vietnam National University Ho Chi Minh City, Ho Chi Minh City, Viet Nam

³Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam

⁴Binh Dinh Pharmaceutical And Medical Equipment Joint Stock Company, Binh Dinh, Viet Nam

⁵Center for Innovative Materials and Architectures, Vietnam National University Ho Chi Minh City, Ho Chi Minh City, Viet Nam

Correspondence

Minh-Tri Le, Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam

Email: leminhtri@ump.edu.vn

History

- Received: 12-7-2024
- Revised: 15-9-2024
- Accepted: 27-12-2024
- Published Online:

DOI :



ABSTRACT

Introduction: Carboplatin is widely used in cancer treatments despite several adverse effects. Metal-organic framework nanoparticles (MOF) were used to load carboplatin, which could improve selectivity to cancerous tissues and control the release profile of this compound. This study aimed to develop and validate a sensitive, simple, cost-effective RP-HPLC method for quantifying carboplatin in MOF.

Methods: This study was developed and optimal different chromatographic conditions for the quantification of carboplatin-loaded MOF materials. The chosen HPLC procedure was validated throughout ICH guidelines.

Results: The chromatographic separation was achieved on an RP-C18 column (250 x 4.6 mm, 5 μ m) by isocartic elution with a mobile phase consisting of methanol: potassium chloride 0.9% in a 1:1 ratio. The flow rate is 1.0 mL/min. PDA detector was used at a wavelength of 254 nm. The validation process has achieved the following criteria: system suitability, specificity, linearity, accuracy, precision, range of determination, and robustness. The method showed linearity in the 0.1-1.5 mg/mL range with R² = 0.9998. The accuracy and %RSD were 98.03-101.37% (mean 99.98%), and 1.08, respectively.

Conclusion: This HPLC method can be used to determine the carboplatin loading and desorption efficiency of MOF materials, including ZIF-8, Zr-UiO-66, and Hf-UiO-66. The method provides a reliable analytical tool for complex MOF compositions, ensuring the safety and efficacy of novel drug delivery systems while accelerating future development in this field.

Key words: Carboplatin, HPLC, quantitative evaluation, MOF materials, drug delivery system

INTRODUCTION

2 Cancer is one of the leading causes of death world-3 wide, which poses a significant burden on the 4 economies of many countries¹. The treatment of can-5 cer often relies on chemotherapy, where drugs are 6 used to kill cancer cells, prevent growth, and inhibit 7 metastasis to other organs². Platinum-based drugs, 8 particularly carboplatin, are widely used in cancer 9 therapy. However, these active ingredients often re-10 quire high doses yet exhibit low selectivity, leading 11 to reduced treatment efficacy and increased adverse ¹² effects³. Recent research efforts have focused on ¹³ the application of metal-organic framework (MOF) nanoparticles as drug delivery systems to overcome 15 these limitations. MOFs have shown promise in load-16 ing and delivering chemotherapeutic agents such as 17 carboplatin, with the potential to protect the active 18 pharmaceutical ingredient from decomposition, en-19 hance bioavailability, and provide controlled release

profiles 456. Previous studies have primarily relied 20 on Inductively Coupled Plasma (ICP) measurements 21 to quantify drug loading onto nanomaterials, which 22 lack the specificity and sensitivity offered by High Per-23 formance Liquid Chromatography (HPLC). Further-24 more, existing HPLC methods for quantifying free 25 carboplatin or carboplatin in injectable formulations 26 cannot be directly applied to accurately determine the 27 drug loading capacity and release efficiency in these 28 novel delivery systems, due to the distinct character-29 istics of carboplatin-loaded MOFs compared to un-30 modified carboplatin. Consequently, there is a need 31 to establish a quantitative method for determining the 32 API in carboplatin-loaded MOF materials and their 33 release profiles, which has a simple procedure, is easy 34 to prepare, and has high accuracy and reliability⁷. The 35 objective of this study is to develop and validate an 36 HPLC method for determining carboplatin in mix-37 tures with MOFs, evaluating the loading and desorp-38 tion efficiency of the corresponding metal-organic-39

Cite this article : Pham T Q, Hoang H D, Nguyen T T, Pham H T T, Nguyen L H T, Doan T L H, Le M. **Developing and validation of high performance liquid chromatography method for determination of carboplatin-loaded Metal-organic framework materials**. *Sci. Tech. Dev. J. - Health Sci.* 2025; 5(2):1-12.

Science & Technology Development Journal - Health Sciences 2025, 5(2):1-12

Copyright

© VNUHCM Press. This is an openaccess article distributed under the terms of the Creative Commons Attribution 4.0 International license.



⁴⁰ framework materials – an approach not previously re-⁴¹ ported in the literature.

42 METHODS

43 Materials

44 Chemical reagents and solutions: Carboplatin ma-45 terial range was kindly provided by Bidiphar (Vietnam) (Lot. No. CA-22060) as a gift and carboplatin 46 standard BP was purchased from Merck (Germany) 47 48 (Lot. No. R152G0). These MOF materials consisting of Zeolitic Imidazolate Framework-8 (ZIF-8), 49 Zirconium-based University of Oslo-66 (Zr-UiO-66), 50 and Hafnium-based University of Oslo-66 (Hf-UiO-51 66) were synthesized according to the published pro-52 cedure of INOMAR. Potassium chloride in analytical grade from Fisher (USA), methanol, and water for 55 HPLC were supplied by Merk (Germany).

56 Instruments: A Shimadzu HPLC system LC-2030 3D

⁵⁷ with a Photo Diode Array (PDA) detector (Japan) was

58 used. Data processing was performed with Lab Solu-

59 tion software (Japan). A Phenonemex Reverse Phase

60 C18 (RP-C18) column (250 x 4.6 mm, 5 μm) (USA)

61 and other precision glassware of analytical grades

⁶² were used for this study.

63 Preparation of solutions

64 Stock solution: Exactly 20.0 mg carboplatin material

65 range was dissolved by 0.9% KCl in a 20 Ml of volu-

⁶⁶ metric flask and then diluted up to the mark.

67 Carboplatin@MOF sample solutions: Weigh exactly

⁶⁸ 5.0 mg of each complex material into amber colored

⁶⁹ flask, and 5 mL stock solution was added. The mix-

⁷⁰ ture was stirred for 24 hours. After centrifuging the ⁷¹ mixture, the supernatant was collected and filtered

⁷² through a 0.45 μ m nylon filter into a 1.5 mL vial.

73 Standard solution: Exactly 20.0 mg carboplatin stan-

74 dard was dissolved by 0.9% KCl in a 20 mL volumetric

⁷⁵ flask and then diluted up to the mark. The solution ⁷⁶ was filtered through a 0.45 μ m nylon filter into a 1.5 ⁷⁷ mL vial.

78 HPLC conditions optimization

79 Determination of detection wavelength: The UV-

⁸⁰ Vis spectrum in HPLC chromatography was used to
⁸¹ determine the maximum absorbance wavelength for
⁸² carboplatin.

- 83 Optimization of method: different ratios of mobile
- 84 phases were tested with an RP-HPLC column and
- 85 PDA detector. The suitable chromatographic condi-

⁸⁶ tions were selected based on the retention time, reso-

⁸⁷ lution, tailing factors, and peak purity.

Validation of analytical method

The developed HPLC with suitable conditions was validated according to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q2 (R1) guidelines for analytical parameters⁸ such as system suitability, specificity, linearity, accuracy, precision, range, limit of detection (LOD), limit of quantitation (LOD), and robustness. 96

88

97

109

116

RESULTS

HPLC conditions optimization

Chromatographic separations were carried out using 99 the Phenomenex RP-C18 column (250 x 4.6 mm; 5 100 μ m) at room temperature with isocartic mode using 101 a mobile phase of methanol and 0.9% KCl in a ratio of 102 1:1. The flow rate was 1.0 mL/min with the injection 103 volume was 20 μ L. All chromatographs were measurements at detection wavelength 254 nm. The result chromatographic showed carboplatin's retention 106 time (t_R) was 2.9 min and had good peak parameters (Figure 1). 108

Validation of analytical method

System suitability: A standard solution was injected and repeated 6 times to record results. Table 1 showed that % Relative Standard Deviation (RSD) of these parameters meets the acceptance required not more than 2.0%. Hence, the method was archived for the system suitability.

Specificity

To confirm the capacity of the analytical method to measure the presence of identified compound separately and specifically from other components in the mixture. In this study, specificity was evaluated for carboplatin, MOF material individually, and the combinations in both normal and stress conditions (stay exposed to light for 24 hours at room temperature). Furthermore, peaks corresponding were also evaluated on peak purity.

Figures 2 to 12 showed a chromatographic of the 126 specificity study, which illustrated that carboplatin 127 completely separated and separated of other components the mixture. The standard solution had only one 129 peak of carboplatin at 2.9 min. In contrast, the blank 130 chromatographic using the diluent did not show any 131 peak. Moreover, the chromatography of each MOF 132 material sample had other peaks but those retention 133 times were different from carboplatin's peak. In the 134 added-standard samples, the carboplatin's peak area 135 and height were increased more than in the basic 136



Table 1: Results of system suitability (n=6)

	•				
S.No	tR (min)	Area (mAU*s)	Tailing factor	Resolution	Theoretic plate count
1	2.932	1283963	1.385	1.629	6461
2	2.929	1281430	1.389	1.719	6466
3	2.930	1280609	1.394	1.809	6420
4	2.930	1280528	1.423	1.901	6533
5	2.933	1283066	1.417	1.953	6340
6	2.932	1269221	1.420	1.966	6446
Mean	2.931	1279802.833	1.405	1.8295	6444
Accepteance criteria	-	-	0.8 - 1.5	≥1.5	> 2000
Standard devia- tion	0.002	5361.975	17.1425	7.408	63.387
%RSD	0.0529	0.419	1.220	0.018	0.983

137 sample, whenever other peaks' parameters were not138 changed.

139 Besides, the stress condition sample for 24 hours illus-

140 trated new purity peaks, which also separated clearly

- 141 from carboplatin's peak (Figures 13 to 15). The result
- 142 in peak purity met the required more than 99.99%.
- 143 Based on this information, the analytical method was
- 144 confirmed specificity parameter.
- 145 Linearity

¹⁴⁶ To evaluate the linearity of carboplatin in this method,

¹⁴⁷ several different concentrations of standard solutions ¹⁴⁸ were prepared concluding with 0.1 – 1.5 mg/mL of ¹⁴⁹ carboplatin content (Table 2). Each concentration was triple injections under the same conditions. The 150 mean of peak areas were used to analyze the calibration curve based on the least square linear regression 152 method. 153

The linear equation of carboplatin was obtained $\hat{y}=$ 154 1282701.83x + 30208.36, and the goodness-of-fit (R²) 155 was found to be 0.9998 (Figure 16), indicating that 156 there is a linear relationship between the concentration of carboplatin and peak area. Hence, the HPLC 158 method met the requirement of linearity in the range of 0.1 to 1.5 mg/mL of carboplatin content. 160 **Precision** 161



Figure 2: Chromatograms of the specificity resultingfrom standard solution



Figure 3: Chromatograms of the specificity resultingfrom blank solution

Table 2: The results of linearity

Concentration (mg/mL)	Peak area	(mAu*s)		Mean (mAu*s)	%RSD
0.1	153253	153262	152895	153136.7	0.137
0.2	288459	288548	289701	288902.7	0.240
0.4	531300	529775	528350	529808.3	0.278
0.5	681842	681722	681234	681599.3	0.047
0.8	1067879	1067839	1067854	1067857	0.002
1.0	1317498	1317331	1315930	1316920	0.065
1.2	1568510	1568153	1565900	1567521	0.090
1.5	1947229	1946988	1947748	1947322	0.019



Figure 4: Chromatograms of the specificity resultingfrom Hf-UiO-66 material



The precision parameter included repeatability and 162 intermediate precision by several measurements of 163 164 standard solution. The repeatability was established by six standard solutions at the 100% concentration 165 levels on the same day. The intermediate precision 166 was established by twelve standard solutions at 100% 167 168 concentration levels, which were prepared by two members on two different days. The RSD of carbo-169 170 platin content was calculated based on the peak area 171 results.

The precision results were shown in Tables 3 and 4,
which indicated the analysis method met the requirements with RSD values (0.103 and 0.260, respectively)

175 of no more than 2%. Using F-test and t-test to statistic 176 the data analysis, the establishment method showed

significant differences between two members on vari-
ance but were not significant differences on average,
and $T_{tn} < T_{0.05}$. Hence, the HPLC procedure archived
the precision parameter.178Accuracy181

To evaluate the accuracy of the method, three standard solutions were prepared by three members at three different times at three concentration levels concluding 50%, 100%, and 150%. Each concentration sample was injected triple. The percentage recovery of added carboplatin and RSD of recovery rate was calculated for those results (Table 5).

The accuracy results showed percentage recovery and 189 RSD values of all solutions at three levels in the range of 98.03-101.37% and 1.08%, respectively. That indi-191



Figure 6: Chromatograms of the specificity resultingfrom CBP@Hf-UiO-66 standard



Table 3: Results of repeatability

Sample No.	Weight (mg)	Peak area (mAu*s)	Content (%)
1	19.9	1315534	99.895
2	20.0	1317498	100.044
3	20.0	1317331	100.031
4	19.9	1315930	99.925
5	20.0	1317736	100.062
6	20.1	1319314	100.182
	Mean (%)		100.023
	%RSD (n =6)		0.103



Figure 8: Chromatograms of the specificity resultingfrom CBP@Zr-UiO-66 sample



¹⁹² cates the ability to apply the method to determine car-

¹⁹³ boplatin in the mixture with MOF materials.

¹⁹⁴ *Range:* Based on these parameters concluding of
¹⁹⁵ linearity, precision, and accuracy, the range of the
¹⁹⁶ method was evaluated by 0.4 – 1.2 mg/mL.

is include was evaluated by 0.1 1.2 mg/im

¹⁹⁷ **Robustness:** Several minor changes in the experimen-¹⁹⁸ tal parameters were analyzed to be evaluated by cal-¹⁹⁹ culated RSD of parameters: flow rate: ± 0.1 mL/min; ²⁰⁰ column temperature: $\pm 2 \ ^{o}$ C; different vial numbers

²⁰¹ in the tray. The results of chromatography indicated
²⁰² the procedure met the requirements of %RSD, tailing
²⁰³ factor, and resolution.

204 **DISCUSSION**

²⁰⁵ This analytical technique, which employs reverse-²⁰⁶ phase chromatography with a PDA detector and an ODS-C18 column, was developed based on the polarization characteristics of carboplatin. The optimized mobile phase (a 1:1 mixture of methanol and 0.9% KCl) enhances the stability of the target compound while facilitating its complete isolation from other substances at 254 nm.

The procedure's efficacy is evident in its ability to isolate carboplatin from diverse components, even under stress conditions, which is crucial for the precise quantification of drug loading and release kinetics in MOF-based delivery systems. Its high sensitivity and specificity are particularly valuable when analyzing complex matrices like MOFs, where potential interference from metallic ions or other elements could impact the precision of the results. This effectiveness has been demonstrated through its application 212



Figure 10: Chromatograms of the specificity resultingfrom ZIF-8 material



to three different MOF materials (ZIF-8, Zr-UiO-66,
and Hf-UiO-66), showcasing its potential for broader
use in optimizing drug delivery systems.

Compared to previous studies that primarily relied 226 on Inductively Coupled Plasma (ICP) measurements 227 to quantify carboplatin loading onto nanomaterials⁹, 228 this HPLC method offers superior specificity and sen-229 sitivity for accurately determining the drug content 230 in carboplatin-loaded MOF systems. Unlike generic 231 232 HPLC methods for free carboplatin or carboplatin 233 in injectable formulations, this technique is specifi-234 cally designed to account for the unique characteris-235 tics of carboplatin-loaded MOFs, enabling more ac-236 curate quantification of drug loading capacity and re-237 lease profiles.

In contrast, the use of UV-Vis spectroscopy for quan- 238 tifying drug loading onto nanomaterials has several 239 drawbacks. UV-Vis measurements often lack the 240 specificity to distinguish carboplatin from other com- 241 ponents in the complex nanomaterial matrix, lead- 242 ing to less accurate quantification¹⁰. Furthermore, 243 the non-specific nature of UV-Vis makes it more 244 prone to interference from other substances present 245 in the nanomaterial samples, compromising the reli- 246 ability of drug content determination. Unlike the tai- 247 lored HPLC technique, generic UV-Vis methods can- 248 not adequately account for the specific behaviors of 249 carboplatin when incorporated into MOF structures. 250 Therefore, the HPLC approach demonstrated in this 251 work offers a more reliable analytical tool for evalu- 252 ating drug-loading capacities and release profiles of 253



Figure 12: Chromatograms of the specificity resultingfrom CBP@ZIF-8 standard



Figure 13: Chromatograms of the specificity resulting from CBP@Hf-UiO-66 in stresscondition

²⁵⁴ carboplatin-loaded MOF materials compared to pre-²⁵⁵ vious techniques.

²⁵⁶ With a broad linear range (0.1 to 1.5 mg/mL) and
²⁵⁷ minimal RSD values, the method ensures accurate
²⁵⁸ quantification across typical concentrations in load²⁵⁹ ing and release experiments. This versatility and ro²⁶⁰ bustness make it suitable for various stages of drug de²⁶¹ livery system development, from initial loading stud²⁶² ies to release kinetics investigations.

263 Adhering to ICH guidelines, the rigorous evaluation

²⁶⁴ process has validated key parameters, including sys-²⁶⁵ tem suitability, specificity, linearity, accuracy, preci-

²⁶⁵ sion, range, and robustness, ensuring reliability and

²⁶⁷ applicability in drug delivery system investigations.

²⁶⁸ This comprehensive validation distinguishes the cur-

²⁶⁹ rent method from previous reports, which may have

lacked such a thorough evaluation of the analytical 270 technique. 271

The utilization of common solvents, reagents, and 272 equipment enhances the technique's accessibility 273 across diverse laboratory settings. This analytical tool 274 enables rapid, cost-effective analysis and facilitates 275 more accurate comparisons between various MOF 276 materials and formulations, ultimately accelerating 277 the development of innovative drug delivery systems. 278

CONCLUSIONS

This research has established and validated an HPLC- ²⁸¹ PDA technique for precise quantification of carboplatin incorporated into MOF structures. The approach enables swift, economical analysis, accurately ²⁸⁴

9

279

280



Figure 14: Chromatograms of the specificity resulting from CBP@Zr-UiO-66 in stresscondition



determining both incorporation and release rates. By
providing a reliable analytical tool for complex MOF
compositions, this methodology not only ensures the
safety and efficacy of novel drug delivery systems but
also lays the groundwork for accelerating future development. Consequently, it proves especially valuable in advancing research within this field in Vietnam.

293 COMPETING INTERESTS

²⁹⁴ The authors declare that they have no competing in-²⁹⁵ terests.

296 AUTHORS' CONTRIBUTIONS

297 Quyen Toan Pham: Methodology, Writing - review
298 & editing, Validation, Visualization, Project admin-

istration, Resources. Hoang-Han Do: Methodology, 299 Validation, Formal analysis, Writing - original draft, 300 Resources. Truc Thanh Nguyen: Investigation, Formal analysis, Writing - original draft. Huong Thi 302 Thanh Pham: Validation, Resources, Visualization. 303 Linh Ho Thuy Nguyen: Conceptualization, Methodology, Writing - review & editing, Visualization. Tan 305 Le Hoang Doan: Conceptualization, Methodology, 306 Writing - review & editing, Visualization. Tri Minh 307 Le: Conceptualization, Methodology, Writing - review & editing, Visualization, Project administration. 309 310

ACKNOWLEDGEMENTS

This research is funded by the Vietnam National University HoChiMinhCity (VNU-HCM) under grant 313

311



Table 4: Results of intermediate precision

Sample	Member 1			Member 2			
	Weight (mg)	Peak area (mAu*s)	Content (%)	Weight (mg)	Peak area (mAu*s)	Content (%)	
1	19.8	1304370	99.047	19.7	1299603	98.685	
2	19.8	1304858	99.084	19.8	1300437	98.748	
3	19.9	1305483	99.132	19.8	1301431	98.824	
4	19.9	1306521	99.210	19.8	1302895	98.935	
5	19.9	1306202	99.186	19.8	1303316	98.967	
6	19.7	1292943	98.179	19.8	1303282	98.964	
	Mean (%)		98.973	Mean (%)		98.854	
	%RSD (n =6)		0.122	%RSD (n =6)		0.398	
	Average content (%) of two members (n = 12): 98.914 %RSD (n=12): 0.260						

Ttn < T0.05 = 2.447

314 number C2022-44-05.

315 **REFERENCES**

- 316 1. Ferlay J, Colombet M, Soerjomataram I, Parkin D, MP, Znaor A,
- et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149(4):778–789. Available from: https://doi.org/
- 319 10.1002/ijc.33588.
- Behranvand N, Nasri F, Emameh RZ, Khani P, Hosseini
 A, Garssen J, et al. Cancer Immunol Immunother.
 2022;71(3):507–526.
- 323 3. Johnstone T, Suntharalingam K, SJ SL, et al. Chem Reviewer.
- 2016;116(5):3436-3486. Available from: https://doi.org/10.

1021/acs.chemrev.5b00597.

 Sun CY, Qin C, Wang XL, Yang GS, Shao KZ, Lan YQ, et al. Zeolitic Imidazolate framework-8 as efficient pH-sensitive drug delivery vehicle. Dalton Trans. 2012;41(23):6906–6909. Available from: https://doi.org/10.1039/C2DT30357D. 329

0.505

- Bůžek D, Adamec S, Lang K, Demel J, et al. Metal-Organic Frameworks vs. Buffers: Case Study of UiO-66 Stability. Inorganic Chemistry Frontiers. 2021;8(3):711–719. 332
- He S, Wu L, Li X, Sun H, Xiong T, Liu J, et al. Metal-organic frameworks for advanced drug delivery. Acta Pharmaceutica Sinica B. 2021;11(8):2362–2395. Available from: https: //doi.org/10.1016/j.apsb.2021.03.019. 336

325

Level (%)	Weight added (mg)	Concentration added (mg/mL)	Mean of peak area (mAu*s)	Concentration recovery (mg/mL)	Recovery (%)
80%	15.3	0.8	1014750.333	0.811	101.369
	15.2	0.8	1014282	0.799	99.892
	15.4	0.8	1026602	0.802	100.270
100%	19.1	1.0	1251560	1.000	100.020
	19.4	1.0	1277511	1.001	100.663
	19.6	1.0	1291088	1.009	100.882
120%	23.3	1.2	1504157	1.202	100.200
	23.2	1.2	1500484	1.182	98.517
	23.5	1.2	1505549	1.176	98.033
Average re	covery rate (%)				99.983
%RSD					1.077

Table 5: Results of accuracy

337 7. Tekkeli S, Kiziltas M, et al. Current HPLC Methods for Assay

- of Nano Drug Delivery Systems. Current Topics in Medici-338
- nal Chemistry. 2017;17(13):1588-1594. Available from: https: 339
- //doi.org/10.2174/1568026616666161222112305. 340
- 341 8. ASEAN. Asean guideline for validation of analytical proce-
- dures. WHO; 2008. 342
- 343 9. Duman FD, Monaco A, Foulkes R, Becer C, Forgan R, et al.
- Glycopolymer- functionalized MOF-808 nanoparticles as a 344
- cancer-targeted dual drug delivery system for carboplatin and 345
- floxuridine. ACS Applied Nano Materials;5(10):13862-13873. 346 Available from: https://doi.org/10.1021/acsanm.2c01632. 347
- 348 10. Savicki C, Camargo N, Gemelli E, et al. Crystallization of carboplatin-loaded onto microporous calcium phosphate 349
- using high-vacuum method: Characterization and release 350
- study. PLoS One;15(12):e0242565. Available from: https: 351
- //doi.org/10.1371/journal.pone.0242565. 352